Evidence review · Published July 22, 2026 · Sources checked July 22, 2026

Thymosin Beta-4 and LKKTETQ fragment research overview

Full-length Thymosin Beta-4 is a 43-amino-acid actin-binding peptide. The catalog material is described as the acetylated 17–23 fragment, Ac-LKKTETQ; these are distinct research materials and should not be conflated.

Evidence boundary: published research does not establish the identity or performance of a separately supplied batch. The catalog product is supplied only for qualified in vitro laboratory research and is not for human or animal use.

What is Thymosin Beta-4 fragment?

One mouse wound study explicitly compared full-length Thymosin Beta-4 with the synthetic LKKTETQ actin-binding domain. Other publications using full-length Thymosin Beta-4 are relevant background but not direct evidence for the fragment.

Research category

Tissue & cellular signaling

Study models represented

Mouse wound models, endothelial cells, and explicit full-length-versus-fragment comparison

Names in the literature

Ac-LKKTETQ; Tβ4 17-23 fragment; LKKTETQ

Primary boundary

Most Thymosin Beta-4 literature is not direct evidence for the isolated Ac-LKKTETQ fragment.

What does the selected evidence support?

Sequence length and N-terminal modification materially affect identity. A study on full-length peptide cannot verify fragment behavior or a catalog batch.

Primary sources

1. Philp et al., Wound Repair and Regeneration (2003) — Mouse wound experiments explicitly testing full-length Thymosin Beta-4 and synthetic LKKTETQ. DOI: 10.1046/j.1524-475X.2003.11105.x
2. Kim and Kwon, Journal of Tissue Engineering and Regenerative Medicine (2017) — Full-length Thymosin Beta-4 endothelial-cell and burn-wound work, included as non-fragment background. DOI: 10.1002/term.2028

Research literature and product documentation are different

A publication describes a study and its results. A batch-specific Certificate of Analysis documents characteristics of a supplied research material. One does not substitute for the other.

Review Thymosin Beta-4 fragment product specifications · Browse the COA library · Read the research-use policy

Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.